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ABSTRACT
Autophagy is a highly conserved catabolic process and amajor cellular pathway for the degradation of long-lived
proteins and cytoplasmic organelles. An increasingbodyof evidence has unveiled autophagy as an indispensable
biological function that helps to maintain normal tissue homeostasis and metabolic fitness that can also lead to
severe consequences for the normal cellular functioning when altered. Recent accumulating data point to
autophagy as a key player in a wide variety of physiological and pathophysiological conditions in the human
endometrium, one of themost proficient self-regenerating tissues in the humanbody and an instrumental player
in placental species reproductive function. The current review highlights the most recent findings regarding the
process of autophagy in the normal and cancerous endometrial tissue. Current research efforts aiming to
therapeutically exploit autophagy and the methodological approaches used are discussed.
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Introduction
Autophagy (a term derived from Greek for “self-eating”) is
a tightly regulated and highly conserved lysosomal degradation
pathway. The autophagy process is induced under various con-
ditions of cellular stress, resulting in the self-degradation of
cellular components. Autophagy is broadly considered as a cell
survival pathway. The process is required to preserve cell fitness
through both nonselective and selective sequestration of macro-
molecules (proteins, lipids, glycogen, and nucleotides) and cel-
lular organelles through a mechanism that involves the
recognition of autophagy selective substrates by specific recep-
tors [1] to sustain metabolism and homeostasis [2].
Three major autophagy routes with distinct molecular fea-
tures have been described and extensively reviewed by other
authors [3–5]. These autophagy pathways are commonly
referred to as chaperone-mediated autophagy (CMA), micro-
autophagy, and macroautophagy [6] (Box 1). Briefly, CMA is
characterized by the direct delivery of single proteins into the
lysosomal lumen through a pathway involving specific indivi-
dual protein recognition by HSPA8 (heat shock protein family
A [HSP70] member 8) cytosolic chaperone and subsequent
lysosomal membrane translocation by interacting with
LAMP2 (lysosomal-associated membrane protein 2) [7].
Interestingly, all proteins internalized by the lysosomes
through the CMA are characterized by a pentapeptide motif
contained within their amino acid sequence (KFERQ). This
pentapeptide is necessary for protein recognition by HSPA8
and lysosome targeting [8]. Meanwhile, microautophagy is
a process in which the lysosome directly engulfs the cytoplas-
mic material through the invagination of the lysosomal mem-
brane [9]. Among the different autophagy pathways, the most
well-known and described route in the endometrial physiol-
ogy is macroautophagy/autophagy. This form of autophagy is
controlled by the highly conserved autophagy-related (ATG)
genes [10]. It is characterized by the sequestration of cyto-
plasmic portions within double-membraned vesicles known as
autophagosomes. Subsequent fusion with the lysosomes gen-
erates de novo structures referred to as autolysosomes. The
final degradation step is triggered by lysosomal hydrolases
[11]. These enzymes generate amino acids and macromole-
cules that are transported across the lysosomal membrane to
the cytosol, where they are reutilized for anabolic processes
[12]. This multi-stage process can be divided into several
steps: initiation, expansion, closure, and fusion with the endo-
lysosomal system [13] (Figure 1).
Functionally, autophagy is gaining momentum as a key
regulator of multiple cellular functions due to its capacity to
prevent the accumulation of cytotoxic products. Normal cel-
lular metabolism, for instance, may generate damaged pro-
teins or organelles and redox-active protein aggregates that
require an intercellular quality control system, such as autop-
hagy [14]. In addition, autophagy responds to disturbances in
intracellular or extracellular homeostasis, thus uncovering
autophagy as a highly dynamic process, as evidenced by its
role during mammalian development and differentiation [15].
It is now apparent that autophagy deficiency or deregulation
is related to various human diseases, such as cancer, as well as
infectious, autoimmune, cardiovascular, rheumatic, pulmon-
ary, metabolic diseases, obesity, aging, and neurodegenerative
disorders (Alzheimer, Parkinson, and Huntington), and is
thus a potential target for therapeutic mediation [5].
In this article, we will review the current knowledge about the
role of autophagy in the endometrium, which is an expanding
area of research due to its key functions in reproductive biology
and regeneration. Accordingly, only in recent years, multiple
studies have pointed to autophagy as an important player in
the normal endometrium physiological processes, as well as in
pathological contexts, such as hyperplasia or endometrial cancer.
These processes involve a constant adaptation to the ever-
changing environment, cell growth, and apoptosis, intimately
linked to autophagy. The current article reviews the most recent
knowledge of the biological and pathological role of autophagy
in the endometrium.
Autophagy in the normal physiology of the
endometrium
The endometrium, or the innermost lining of the uterine
cavity, is one of the most dynamic tissues in the human
body. The other layers that compose the uterine wall are the
myometrium or the middle layer, a muscular layer composed
mainly by uterine smooth muscle, and the outermost serosal
layer or perimetrium that covers the uterus.
Morphologically, the human endometrium is divided into
two layers: the functional layer and the basal layer. The func-
tional layer represents two-thirds of the endometrial thickness
and comprises of different cellular components, including the
glandular epithelium, endometrial stromal cells, fibroblasts,
immunocompetent cells, and the vascular compartments
[16,17]. Correct assembly of all these components concocts
a dynamic tissue, which is under the control of estrogen and
progesterone, that undergoes a complex series of cyclical
changes during reproductive life in preparation for embryonic
implantation and subsequent shedding and regeneration in
the non-conceptive cycle [18].
Menstrual cycle
Distinct histologic phases are recognized during the menstrual
cycle, which are: (i) menstrual phase, (ii) proliferative phase, and
(iii) secretory phase (early secretory, mid-secretory, and late-
secretory phases) (Figure 2). The first day of menstrual bleeding
corresponds to the beginning of the endometrial cycle and
results from the reduction in estrogen and progesterone
Box 1. Definitions
Autophagy: An intracellular catalytic process that recycles damaged cellular
organelles and other constituents by delivering them into the lysosomes.
Chaperone-mediated autophagy: a form of autophagy characterized by the
delivery and degradation of cellular constituents by a chaperone-
dependent selective process.
Microautophagy: a form of autophagy whereby cellular cargo is degraded
within lysosomes by direct lysosomal/vacuolar engulfment.
Macroautophagy: a form of autophagy characterized by the formation of
double-membrane vesicles that will fuse with the lysosomes to degrade
organelles and other cellular components.
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concentrations. This hormone reduction leads to a constriction
of spiral arteries and ischemic necrosis of the functional endo-
metrium layer. During the late-secretory phase and the men-
strual phase, apoptosis seems to facilitate the elimination of the
senescent endometrial cells from the functional layer of the
endometrium [19]. This phase is followed by the proliferative
phase, characterized by the progressive increase in the synthesis
and secretion of estradiol and concomitant thickening of the
endometrium. Then, during the secretory phase, the ovaries
produce progesterone [20], which plays an important role in
preparing the endometrium for the blastocyst implantation by
boosting blood flow, uterine secretions, and by reducing the
contractility of the smooth muscle layer. In the absence of
implantation, withdrawal of estrogen and progesterone leads to
the vasoconstriction of spiral arteries, resulting in the involution
of the endometrium and restarting of the menstrual cycle. In this
context, Choi et al. demonstrated that endometrial cell autop-
hagy is controlled by ovarian steroids and closely correlates with
apoptosis during the secretory and menstruating phases.
Specifically, the authors observed increased levels of lipidated
MAP1LC3A/LC3A (microtubule associated protein 1 light chain







































































Figure 1. Schematic representation of the autophagy process. Autophagy is a multi-stage process that comprises several steps: initiation, expansion, closure, and
fusion with the endolysosomal system. The process initiates with the progressive sequestration of a portion of the cytoplasm that is enclosed within a double-
membrane (a phagophore) to finally form an autophagosome. The initiation involves the transmission of the autophagy signal, which is triggered by multiple
conditions, such as nutrient starvation, and canalized through specific cell sensors such as AMP-activated protein kinase (AMPK), HIF1A (hypoxia-inducible factor
alpha) and mechanistic target of rapamycin kinase complex 1 (MTORC1) to the membrane of origin at which the nucleation takes place. As a consequence, there is
a recruitment of the key initiation complexes. The ULK1 (unc-51 like autophagy activating kinase 1) complex plays a central role in the initiation stage, and it is the
target of these signaling pathways and, when activated, triggers the nucleation of the phagophore by phosphorylating components of the class III phosphatidy-
linositol 3-kinase (PtdIns3k) complex I. Then, WIPI2 (WD repeat domain, phosphoinositide interacting 2), and ZFYVE1 (zinc finger FYVE domain containing 1) are
recruited to the omegasome. WIPI2 binds and is activated by phosphatidylinositol 3-phosphate (PtdIns3P). Once activated, WIPI2 recruits at phagophore assembly
sites the ATG12–ATG5-ATG16L1 complex that enhances the ATG3-mediated conjugation of LC3 (microtubule-associated protein light chain 3) to phosphatidyletha-
nolamine. LC3-I is converted into its lipidated form, LC3-II. Membrane material for the nucleation of the phagophore and the elongation of the autophagic
membrane arises from the ER, mitochondria, recycling endosomes, Golgi apparatus, and plasma membrane from which ATG9-containing vesicles provide portions of
lipid bilayers. Finally, the expansion continues until the complete formation and closure of the autophagosome. The outer membrane of the autophagosome
subsequently fuses with the lysosome, giving rise to the autolysosome. After lysosomal digestion, the sequestered cytoplasmic material is degraded into amino acids
and macromolecules, transported across the lysosomal membrane to the cytosol, and finally recycled for anabolic processes.
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correlates with cleaved CASP3 (caspase 3). Autophagy and
apoptosis present a close relationship during the menstrual
cycle [21]. Importantly, the authors also demonstrated that
ovarian hormones regulate autophagy in endometrial cancer
cells in vitro. LC3A-II levels increase in Ishikawa cells deprived
of estrogen and/or progesterone. The autophagy inhibitor bafi-
lomycin A1 (Baf A1), promotes autophagosome accumulation
and increases the BAX:BCL2 (BCL2 associated X, apoptosis
regulator:BCL2 apoptosis regulator) ratio and cleaved CASP3
thereby, triggering an apoptotic response.
Implantation
Implantation is a coordinated process involving a functional
blastocyst, a receptive endometrium, a synchronized transfor-
mation, and an adequate cross-communication between
embryonic and maternal tissues. The process, ultimately,
results in the blastocyst adherence to the uterine wall and
nourishment [22] (Box 2).
During implantation, the endometrium must suffer several
adaptations to ensure the development of a proper feto-
maternal interface. Changes in the uterine mucosa are
known as decidual reaction, decidualization, or transforma-
tion into a decidua. Decidualization is characterized by the
differentiation and conversion of the endometrial stromal
cells into epithelioid-like cells to accommodate pregnancy
[23] (Box 2). Both resultant specialized secretory decidual
cells that supply nutrients and an immune-favorable
microenvironment are necessary for successful implantation
and placentation [24]. This process occurs in the area where
the blastocyst and the endometrial decidua contact and
requires a postovulatory increase of progesterone and local
cAMP levels [24]. It involves swelling of all endometrial
stromal cells, due to the accumulation of lipid granules, glyco-
gen, and other nutrients, to enable the survival of the embryo
until the placenta is completely developed [23]. The process of
epithelioid differentiation that occurs during decidualization
also involves an increase in the complexity and number of the
nucleoli, accumulation of lipid droplets and glycogen into the
cytoplasm, and an increase and dilatation of rough ER (endo-
plasmic reticulum) and Golgi apparatus [25,26].
Interestingly, recent pieces of evidence suggest that autop-
hagy favors decidualization as indicated by the remarkable pre-
sence of MAP1LC3/LC3 (microtubule-associated protein light
chain 3/LC3-I), converted LC3-II expression, and autophago-
somes in normal, abnormal villous and decidual specimens from
early pregnancies [27]. An additional study recently demon-
strated that autophagic flux is increased during decidualization
using an immortalized cell line of human endometrial stromal
cells. Importantly, knockdowns of ATG7 and ATG5 impair
decidualization, confirming the role of these ATG proteins in
the human endometrial decidualization [28]. In support of this,
Rhee et al. used an obese mouse model to demonstrate that
impaired autophagy is linked to a decrease in decidualization
and obesity-related infertility [29]. Obesity has been shown to
exert negative effects on reproduction and correlated with
decreased pregnancy rates, infertility [30], increased early preg-
nancy loss [31], and poor oocyte quality [32]. Rhee et al. demon-
strated that diet-induced obesity reduces endometrial stromal
cell decidualization, implantation, and early fetal growth [29].
Interestingly, the authors observed that autophagy is induced
during decidualization, and characterized by increased levels of
ACACA (acetyl-CoA carboxylase alpha), p-ACACA and
p-ULK1 (unc-51 like autophagy activating kinase 1). These
autophagy markers are significantly decreased in decidualizing
cells from obese females. Not surprisingly, the authors reported
a higher autophagic flux in decidualized cells since the expres-
sion of LC3B-II increases with decidualization in human endo-
metrial stromal cells exposed to Baf A1. This effect is abolished
after palmitic acid exposure. The results point at an intriguing
link between autophagy and obesity in the context of reproduc-
tive fitness. Autophagy inducers may provide a potential ther-
apeutic for the treatment of obesity-associated subfertility.
Noteworthy, a role for autophagy has also been
demonstrated in the context of oocytogenesis, embryogen-















Figure 2. Illustration of endometrial layers and tissue components dynamic changes
during the course of the different phases of the menstrual cycle. The endometrium,
composed of a single layer of columnar epithelial cells plus stroma, can be sub-
divided into two layers: the functional, which faces the uterine cavity, and the basal
layer in direct contact with themyometrium. Both layers undergo structural changes
during themenstrual cycle. Menstruation constitutes the first phase of themenstrual
cycle, and it is characterized by the complete desquamation of the functional layer of
the endometrium and bleeding (menses). This stage precedes the proliferative
phase, characterized by the increase in the synthesis and secretion of estrogens as
the ovarian folliclesmature (ovarian follicular phase). The estrogens will promote the
regeneration of the functional layer from the basal layer of the endometrium. By day
14, a peak in LH secretion triggers a decrease in estrogen production, ovulation, and
the formation of the corpus luteum (luteal ovarian phase), which represents the
primary source of progesterone. Progesterone will prepare the endometrium for
future implantation by fostering global endometrial thickening characterized by
increased spiral artery length and coiling, uterine secretions, and reduced smooth
muscle cell contractility. In the absence of pregnancy, the demise of the corpus
luteum will cause a dramatic drop in the progesterone and estrogen levels, and the
initiation of the menstruation starts again.
Box 2. Definitions
Implantation: a coordinated process by which the blastocyst orientates,
attaches, invades, and finally embeds itself into the maternal endometrium.
Decidualization: the differentiation process that undergoes endometrial
fibroblast-like mesenchymal stromal cells to epithelioid-like cells in order to
accommodate pregnancy.
Menopause: a condition that develops at the end of lifelong menstrual cycles
characterized by an insufficient stimulation of the endometrium in response
to a primary ovarian failure and a dramatic decrease of circulating estrogen.
The endometrium might become thinner as a result of low estrogen levels
and is described as being atrophic.
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autophagy has been linked to spontaneous abortion, poor
placentation, pre-eclampsia, and intrauterine growth
restriction [33].
Atrophic endometrium
Menopause is characterized by an insufficient stimulation
of the endometrium in response to a primary ovarian
failure and a dramatic decrease in circulating estrogen
(Box 2). The endometrium may become thinner as
a result of low estrogen levels and is described as being
atrophic. Autophagy has been described as a potential
molecular mechanism responsible for estrogen withdra-
wal-induced endometrium atrophy [34,35]. Indeed, autop-
hagy is activated in the uterine epithelial cells of both
oophorectomized rats and peri-menopausal women and
correlated with apoptosis [34]. After oophorectomy, the
uterine endometrium of rats becomes atrophic in a time-
dependent manner. ER stress precedes this response by
inactivating the AKT (AKT serine/threonine kinase)-
MTOR (mechanistic target of rapamycin kinase) signaling
pathway in vitro and in vivo through the inhibition of the
arachidonic acid-prostaglandin E2 axis. These events
result in increased autophagosomes and LC3-dependent
autophagy in the atrophic endometrium. Similarly, the
exposure of primary epithelial cells to the estrogen inhi-
bitor, letrozole, leads to elevated autophagic flux and
apoptotic response characterized by increased BAX,
BCL2, and active CASP3 protein levels. Importantly,
administration of exogenous 17β-estradiol, prostaglandin
E2, or salubrinal, and silencing of ATG5 and BECN1
(beclin 1) counterbalance these effects. Tissue-level analy-
sis demonstrated that, while premenopausal uterine
epithelial cells present low autophagy level and death,
apoptosis in postmenopausal uterine epithelial cells is
concomitant with autophagy. Altogether, these findings
point to autophagy and estrogen withdrawal as regulators
of the endometrial atrophy and suggest that autophagy
may induce apoptotic cell death.
The transition to menopause is characterized by an
increase in serum FSH (follicle-stimulating hormone), and
a decrease in estradiol and inhibin levels [36]. Recent pieces
of evidence demonstrate that FSH participates in age-related
endometrial atrophy, partly through regulation of the autop-
hagy pathway [35]. Surgical oophorectomy in mice results in
endometrium alterations, such as smaller glandular tube size,
vacuolization in mitochondria, pyknotic nuclei, and
a hollowed rough ER. In line with this, FSH inhibits cell
proliferation and promotes apoptosis of primary endometrial
cells. FSH increases CASP3, CASP8 (caspase 8), and CASP9
(caspase 9) apoptosis markers and the protein expression of
the autophagy-related genes ATG3, ATG5, ATG7, ATG12
and LC3A/B in endometrial adenocytes. Additional mechan-
istic studies showed that the autophagy-related genes are
transcriptionally regulated by the FSH-TGFBR2 (transform-
ing growth factor beta receptor 2)-SMAD2 (SMAD family
member 2)-SMAD3 signaling axis.
Autophagy in the pathologic endometrium
Hyperplasia
Endometrial hyperplasia (EH) is defined by the abnormal
thickening of the endometrium. It is characterized by the
irregular proliferation of endometrial glands and an increase
in the gland-to-stroma ratio in comparison to the proliferative
endometrium [37]. EH comprises both benign and/or prema-
lignant lesions since certain atypical forms are considered
a precursor lesion of endometrial cancer (EC) [38,39].
Therefore, an accurate diagnosis that can discriminate
between these two situations is essential for optimal patient
management. Two different, yet overlapping, histomorpholo-
gical systems are used to classify premalignant endometrial
lesions: i) the World Health Organization (WHO) system of
endometrial hyperplasia with or without atypia, which differ-
entiates a high-risk from a low-risk of synchronous or sub-
sequent adenocarcinoma based on the presence or absence of
cytologic atypia and ii) the endometrial intraepithelial neopla-
sia system defined as a clonal proliferation of architecturally
or cytologically altered endometrial glands [40].
Chronic exposure of the endometrium to excessive or unopposed
estrogen stimulation may result in EH. A well-known paradigm of
treatment-induced EH is the chronic exposure to tamoxifen,
a selective ESR1 (estrogen receptor 1) modulator. Tamoxifen is
widely used in pre-menopausal women with ESR1-positive breast
cancer, and it is the standard treatment in post-menopausal women
with breast cancer. However, while presenting ESR1 antagonistic
effects in the breast, tamoxifen exerts agonistic effects in other tissues,
such as the uterus. Indeed, long-term tamoxifen treatment increases
the incidence of EH and endometrial cancer [41]. Additionally,
tamoxifen has been shown to activate the transcription of several
ESR1 target genes in endometrial cells, such as PAX2 (paired box 2),
ERVW-1 (endogenous retrovirus groupWmember 1, envelope) [42]
and NR5A1 (nuclear receptor subfamily 5 group A member 1) [43].
Tamoxifen promotes EH by activating PRKCD (protein kinase
C delta) and by inducing NFE2L2 (nuclear factor, erythroid 2
like 2) phosphorylation at serine 40. Upon phosphorylation,
NFE2L2 translocates into the nucleus and leads to increased tran-
scription of the autophagy-related receptor SQSTM1 (sequesto-
some 1) [41]. Interestingly, tamoxifen-mediated tumor growth is
attenuated upon SQSTM1 knockdown in RL95-2 and AN3CA
endometrial cancer cells but not in breast cancer cells. In vivo,
a chemical inhibitor of NFE2L2 reverts tamoxifen-induced hyper-
plasia in endometrial cells but not in breast cancer cells.
Other complementary studies also linked autophagy to EH. For
instance, Sivridis et al. studied the LC3A reactivity by immunohis-
tochemistry in a series of endometrial cancer, hyperplasia, and nor-
mal endometrium [44]. LC3A reactivity was characterized by three
staining patterns: i) diffuse cytoplasmic, ii) cytoplasmic/juxta-nuclear,
and iii) spheroidal structures enclosed within the cytoplasmic
vacuoles, described as “stone-like” structures (SLS). Both cytoplasmic
diffusion and juxta-nuclear patterns are associated with basal autop-
hagy activity. The SLS pattern is observed in malignant epithelial
cells, reflecting an increased or an abnormal autophagy level.
Interestingly, the LC3A-positive SLS staining is also present in
a small fraction of atypical hyperplasias. The authors suggested that
the SLS counts could be a potential diagnostic tool to differentiate
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grade-1 endometrioid adenocarcinomas from atypical hyperplasias.
The study suggested that autophagy is altered in endometrial hyper-
plasias and specifically increased in atypical hyperplasias.
Endometrial cancer
Endometrial cancer (EC) is the most common gynecologic
malignancy in the Western world, with more than 320,000
estimated new cases worldwide in 2012 [45,46]. EC incidence
has increased by 21% since 2008, probably related to the
increasing life span and obesity rates [47]. In 1983,
Bokhman et al. described a dualistic model of endometrial
cancer based on clinical, pathological, and molecular features
[48]. This model broadly categorizes EC to type I and type II
tumors and has been used to classify EC up to present. Type
I ECs account for ~75% of diagnosed ECs, typically repre-
senting low-grade estrogen-dependent tumors that mostly
develop in perimenopausal women and are frequently asso-
ciated with hyperplastic precursor lesions. On the other hand,
type II ECs tend to be estrogen-independent tumors, with
most cases occurring in postmenopausal women. They are
aggressive tumors with a poorer clinical outcome and include
mostly serous and clear cell histological subtypes [49].
Contrary to type I, type II ECs are more frequently associated
with endometrial atrophy. In addition to the clinical and
pathological aspects, the differences between type I and type
II tumors can be partially attributed to divergent alterations
at a molecular level. While type I tumors present mutations
in PTEN (phosphatase and tensin homolog), KRAS (KRAS
proto-oncogene, GTPase), PIK3CA (phosphatidylinositol-
4,5-bisphosphate 3-kinase catalytic subunit alpha) and
CTNNB1 (catenin beta 1), as well as microsatellite instability,
type II tumors show alterations in TP53 (tumor protein p53),
loss of heterozygosity on several chromosomes, as well as
other representative molecular alterations (CDH1 [cad-
herin 1], ERBB2 [er-b2 receptor tyrosine kinase 2] and
CDKN2A [cyclin dependent kinase inhibitor 2A]) [50,51].
Although the dualistic classification has been broadly used,
it is not entirely robust since some endometrial cancers pre-
sent shared characteristics of both types I and type II ECs.
Recently, a new molecular classification of EC profiling has
shed light on the different genomic subtypes and may facil-
itate the development of tailored treatments and improved
patient management [52].
Autophagy in endometrial cancer development
The aforementioned study by Sivridis et al. [44] found that
the number of SLS is significantly higher in EC specimens,
compared to hyperplasias or healthy tissues. Contrary to the
diffuse and the juxta-nuclear staining, which are related to
a basal level of autophagy and low malignant potential, SLS-
positive staining is associated with highly aggressive tumors,
exaggerated autophagy levels, and a dramatic decrease in the
5-year survival. The authors stratified EC cases by favorable
and unfavorable prognosis, revealing a first group largely
represented by a low-grade endometrioid adenocarcinoma
and the second one composed of serous, clear cell, and
grade 2–3 endometroid ECs. Intriguingly, even in the high-
grade tumors group, the presence of a high SLS count is
associated with significantly worse prognosis, underscoring
a potential role for autophagy in tumor aggressiveness.
More recently, another study examined the data from The
Cancer Genome Atlas from 11 cancer types to analyze a set of
211 human autophagy-related genes establishing correlations
with tumor-associated DNA alterations and RNA expression
[53]. Lebovitz et al. excellently reported EC as the tumor type
presenting the highest number of significantly autophagy-
associated mutated genes. Mutations include core autophagy
genes (ATG4 C [autophagy related 4 C cysteine peptidase],
ULK4 [unc-51 like kinase 4], and RB1CC1/FIP200 [RB1 indu-
cible coiled-coil 1]), along with MTOR-activating mutations.
Interestingly, practically all of the mutations are found in
patients of the endometrioid subtype and include patients
presenting double mutants for MTOR and PTEN, and patients
presenting either a truncating mutation or a predicted dama-
ging substitution in the autophagy inducer RB1CC1. These
results imply that autophagy execution may be compromised
in endometrioid tumors as a result of hyperactivation of
MTOR, or inactivating mutations in core autophagy compo-
nents such as RB1CC1. In contrast, non-endometrioid tumors
exhibit an increase in mRNA levels of CDKN2A, an autop-
hagy activator [54], and a biomarker that is highly expressed
in serous compared to endometrioid EC [55].
Aberrant expression of other autophagy core components
has also been reported in EC. For instance, increased BECN1
expression has been observed in endometrioid EC and asso-
ciated with poor prognostic factors, such as high tumor grade,
myometrial invasion, and low estimated 5-year survival [56].
A positive correlation between BECN1 and HIF1A (hypoxia
inducible factor 1 alpha) levels suggests a role for BECN1 in
tumor survival in hypoxic microenvironments. In contrast to
these findings, another study observed a decrease in BECN1
and PTEN from normal endometria throughout the neoplas-
tic transformation, including hyperplasia and carcinoma tran-
sition [57]. However, in this case, the expression of BECN1
has been correlated only with cell differentiation and histolo-
gical type. No correlations with the myometrial infiltration or
the pathologic stage of the tumor have been reported.
Another molecule linked to EC and autophagy is KIAA1324/
EIG121, a transmembrane protein associated with intracellular
membrane trafficking, endosomes, and autophagy activation [58].
KIAA1324 is highly expressed in complex hyperplasia and low-
grade endometrioid tumors but decreased in non-endometroid
tumors [59]. KIAA1324 overexpression in vitro increases autop-
hagy levels, as observed by the accumulated autophagosomes, LC3
punctuated dot-like structures, acidic vesicles, and long-lived pro-
tein lysosomal degradation. In contrast, KIA1324 knockdown
decreases cell survival during starvation or stress by using cyto-
toxic agents, suggesting its role in protecting cancer cell survival
under hostile conditions through autophagy induction [60].
In conclusion, a vast amount of evidence suggests that autop-
hagymay contribute to ECdevelopment by enabling cell survival in
unfavorable conditions, like starvation or hypoxia. In addition,
although further studies are required, high CDKN2AmRNA levels
and SLS counts in the more aggressive non-endometrioid subtype
may indicate higher autophagy induction. In comparison, the
endometrioid subtype may exhibit a lower level of autophagy
competence due to genome DNA mutations.
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Targeting autophagy as a therapeutic approach in
endometrial cancer
EC generally presents a favorable prognosis due to its early
detection, when primary surgical treatment is frequently cura-
tive, reaching 5-year survival rates over 70%. Despite being
treated according to their assessed risk, ~15-20% of these
early-diagnosed patients continue to relapse after surgery.
Recurrences typically affect the vaginal or pelvic regions and
may include metastasis to distant sites [61,62]. Consequently,
patients diagnosed at the advanced-stages or patients present-
ing high-risk factors receive a more aggressive treatment after
primary surgery. Treatments are based on adjuvant radiation
therapy, chemotherapy, or the combination of both. However,
these treatments tend to fail and are estimated to benefit only
10–15% of all patients [63]. The prognosis of patients with
recurred or advanced (metastatic) EC is consequently poor,
with median survival rates of less than 1 year and a median
progression-free survival rates of 4 months [64]. These clinical
features underscore the need to develop improved targeted
therapies and novel strategies to overcome cancer resistance
[65]. Several efforts have been made to determine the poten-
tial therapeutic benefit of autophagy modulation as a novel
treatment for EC. Over the last decade, the number of studies
assessing the role of autophagy during EC response to therapy
has grown exponentially. While numerous articles report
a role for autophagy in response to multiple agents, these
publications do not follow common, systematic, and standar-
dized protocols to study autophagy. Major research findings
involving the use of potential therapeutic drug compounds to
treat EC (mechanism of action and autophagy modulation)
are summarized in Table 1.
Currently, systemic therapy for EC mainly entails the use of
platinum-based and taxane compounds. However, available
options after the first-line treatment when cancer recurs are
limited, thus evidencing the need for novel therapeutic drugs
to overcome EC chemoresistance [66]. Although the role of
autophagy in cancer is complex and context-dependent, increas-
ing pieces of evidence suggest that chemotherapeutic agents may
activate an autophagy pro-survival response in cancer cells
[67,68]. Inhibition of autophagy may re-sensitize chemoresistant
cancer cells to conventional therapy. Importantly, autophagy
inhibition increased cell sensitivity in response to a lower drug
concentration and, consequently, may help reduce side effects.
Conversely, chemotherapeutic agents have also been shown to
trigger an autophagy response that leads to cell death, mainly in
apoptosis-defective cells [69]. This notion suggests a therapeutic
strategy based on an over-stimulation or excessive autophagy.
Further characterization of the autophagy-dependent adaptive
mechanisms in cancer cells is crucial to overcome drug resis-
tance and to improve drug efficacy.
Cisplatin and combination therapies. Chloroquine (CQ) is
an autophagy inhibitor that increases the lysosomal pH. CQ
treatment blocks the fusion of autophagosomes with lyso-
somes and subsequent lysosomal protein degradation, thereby
promoting autophagosome accumulation [70]. In Ishikawa,
KLE, and AN3CA cell lines, CQ treatment increases the
accumulation of LC3-II and SQSTM1 and suppresses cell
proliferation via the induction of apoptosis [71]. These CQ
effects, then, decrease after ATG5 or ATG7 silencing. It was
shown that cisplatin induces autophagy in Ishikawa cells, and
either ATG5 or ATG7 knockdown significantly increases cell
sensitivity to cisplatin. Furthermore, the combination of cis-
platin and CQ in cisplatin-resistant cells enhances their sensi-
tivity to cisplatin. These results indicate that the induction of
autophagy protects cancer cells against cancer treatment.
Similarly, Sun M et al. reported that Ishikawa cisplatin-
resistant cells present higher autophagy levels compared to
cisplatin-sensitive parental cells [72]. The authors performed
long-non-coding RNA (lncRNA) profiling to identify differ-
entially expressed lncRNAs involved in the regulation of cis-
platin-induced autophagy. Among the differentially expressed
lncRNAs, HOTAIR (HOX transcript antisense RNA) is sig-
nificantly downregulated in resistant cells. Interestingly, the
authors found that HOTAIR regulates the expression of
BECN1. Downregulation of HOTAIR by siRNA increases
autophagy and apoptosis in Ishikawa cisplatin-resistant cells.
Remarkably, a dual-color DsRed-LC3-GFP reporter was used
to study the increased autophagic flux, representing one of the
few studies in EC using the state-of-the-art methodology.
However, despite evidence of increased autophagic flux in
resistant cells, no GFP+, RFP+, or double GFP+ RFP+ puncta
per cell were quantified. The protective role of autophagy in
this context is still unclear, as cell survival and autophagic flux
were not evaluated upon autophagy inhibition using conven-
tional agents (e.g., CQ) and upon decreased expression of
HOTAIR, respectively.
Finally, another group found that cisplatin exposure in
Ishikawa EC cells induces an autophagy response, with
the increased number of autophagosomes and LC3
expression through inactivation of the PIK3CA-AKT-
MTOR signaling pathway [73]. This inhibition is partially
reversed by co-treatment with IGF1 (insulin like growth
factor 1), a PIK3CA activator.
Proteasome inhibitors. An additional class of compounds
that affect autophagy levels are proteasome inhibitors. One
example is bortezomib, an inhibitor of the 26S proteasome
used in the treatment of multiple myeloma [74]. Bortezomib
also presents anti-tumoral effect in other malignancies, such
as endometrial [75], breast [76], colon [77], and prostate
cancer [78]. It has been described that bortezomib, by stabi-
lizing NFKBIA (NFKB inhibitor alpha), blocks the activity of
the NFKB (nuclear factor kappa B) signaling pathway, result-
ing in the downregulation of its anti-apoptotic target genes,
increasing the sensitivity of cancer cells to chemotherapy [79].
Treatment with CQ or bortezomib increases SQSTM1 and
LC3-II in ovarian, endometrial, and hepatocellular cancer
cells [80]. However, bortezomib blocks the autophagic flux
without inhibiting the fusion of autophagosomes with lyso-
somes, which may be due to suppressed cathepsin activities by
EPHB2/ERK (EPH receptor B2) phosphorylation.
Histone deacetylase inhibitors. Histone acetylation modifica-
tions are responsible for the changes in the chromatin struc-
ture and the accessibility of genes for the transcriptional
machinery and have a crucial role in epigenetic regulation of
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as potential therapeutic agents in cancer treatment [81],
including EC [82]. Suppression of sirtuin (SIRT) proteins
and signaling by the novel SIRT inhibitor, MHY2256, results
in cell cycle arrest in vitro and impaired tumor growth in
a tumor xenograft mouse model of Ishikawa cells. MHY2256
induces early and late-stage apoptosis and autophagy, as
shown by an increase in the levels of LC3-II, ATG5, and
acidic vesicular organelles. MHY2256 exerts its antitumori-
genic properties through TP53 acetylation.
Enhanced NK cytotoxic activity. Other studies have elegantly
assessed the effects of cisplatin and autophagy modulation in
the tumor microenvironment. For instance, a recent study
suggested that rapamycin and cisplatin co-therapy may
improve EC treatment by stimulating cytotoxicity of natural
killer (NK) cells [83]. NK cells are a type of innate cytotoxic
lymphoid cells and are critical for controlling neoplastic
development, tumor growth, metastatic spread, and determin-
ing tumor chemosensitivity [84]. Zhou et al. reported
a positive correlation between rapamycin treatment and
increased IL27 (interleukin 27) expression, which impacts
the degree of tumor differentiation. By implementing a co-
culture system, the authors demonstrated that overexpression
of IL27 or treatment with rapamycin in Ishikawa, RL95-2, and
KLE cells enhances the cytotoxic activity of NK cells. This
impairs EC tumor growth in a xenograft mouse model.
Mechanistically, IL27 enhances rapamycin-induced autophagy
through the upregulation of BECN1 and LC3B mRNA levels
[83]. Rapamycin combined with a classical cytotoxic agent
(e.g., cisplatin) might be an improved therapy for EC, parti-
cularly in patients with poorly differentiated carcinomas or
abnormally low expression levels of IL27.
Carboplatin, paclitaxel and combination therapies. Based on
its response rates, the combination of carboplatin and pacli-
taxel is the standard regimen of EC treatment [66,85,86].
A recent study pointed to ABTL0812, a novel class of chemi-
cally modified fatty acid-derived small molecule, as an effec-
tive compound acting on the PIK3CA-AKT-MTORC1
(mechanistic target of rapamycin kinase complex 1) axis
[87]. ABTL0812 induces autophagy-mediated cell death by
inhibiting the AKT-MTOR axis through TRIB3 (tribbles
pseudokinase 3) upregulation, an endogenous AKT inhibitor.
The molecule also induces ER stress in vitro and in vivo.
ABTL0812 reduces cell viability and increases cell death in
Ishikawa, AN3CA, HEC-1A, ARK1, and ARK2 EC cell lines
(CASP9 and CASP3). Concomitant with upregulated TRIB3
expression and reduced phosphorylation of AKT and
RPS6KB1 (ribosomal protein S6 kinase B1), ABTL0812
increases the levels of LC3-II and the autophagic flux, quan-
tified by using a chimeric mRFP-GFP tandem fluorescent-
tagged LC3B construct (tfLC3). In addition, ABTL0812
impairs tumor progression in patient-derived xenograft
(PDX) EC models (endometrioid and serous) and presents
a similar efficacy to the standard first-line treatment (carbo-
platin-paclitaxel). The authors further demonstrated that
ABTL0812 has a synergistic effect when combined with
carboplatin-paclitaxel in the serous PDX model. Using an
inducible pten knockout mice model, which carries Pten-
floxed alleles (Ptenfl/fl), and the tamoxifen-induced CRE
recombinase (Cre:Ers+/−) under the estrogen promoter, the
authors observed that ABTL0812 treatment impairs pten
knockout cells to progress from hyperplasia to cancer.
Interestingly, ABTL0812 reduces proliferation and induces
autophagy exclusively in pathogenic but not in healthy endo-
metrial cells using 3D cultures. A phase 1b/2a clinical trial for
the evaluation of ABTL0812 in patients with EC is ongoing
(NCT03366480).
In another study, paclitaxel resistance in EC was tested using
HEC-1A, JEC, Ishikawa, and AN3CA EC cell lines. HEC-1A
and JEC cells, respectively, present the highest IC50 values and
are considered paclitaxel-resistant cells [88]. Paclitaxel induces
autophagy in paclitaxel-insensitive HEC-1A and JEC cells. It
increases the LC3-II:LC3-I ratio, LC3 punctate dots in the
cytosol, BECN1 levels, and decreases SQSTM1 but not in the
paclitaxel-sensitive Ishikawa and AN3CA cell lines. Treatment
with both paclitaxel and CQ, or BECN1 shRNA, enhances cell
death. This result suggested that paclitaxel-induced autophagy
in EC-resistant cells plays a cytoprotective role. Mechanistically,
paclitaxel stimulates the generation of reactive oxygen species,
that, when inhibited, blocks paclitaxel-induced autophagy.
Therefore, an autophagy inhibitor treatment in combination
with paclitaxel may be an effective treatment in EC.
Ran et al. identified the MIR218 as significantly down-
regulated in Ishikawa and RL95-2 paclitaxel-resistant cells.
MIR218 inversely correlates with the increased autophagy
levels, indicated by accumulation of LC3 puncta, high LC3-
II:LC3-I ratio, and BECN1 expression [89]. Overexpression of
MIR218 re-sensitizes resistant EC cells to paclitaxel by inter-
acting with the 3ʹ-UTR of HMGB1 (high mobility group
box 1). Accordingly, HMGB1 knockout by using transcription
activator-like effector nuclease (TALEN) technology decreases
the autophagy levels in paclitaxel-treated cells.
On the contrary, another study found that treatment with
RAD001 (everolimus), an inhibitor of MTOR, induces autop-
hagy-dependent cell death in Ishikawa and HEC-1A EC cells,
and increases their sensitivity to low-dose paclitaxel [90]. This
result suggests that the combination of RAD001 with pacli-
taxel may reduce the cytotoxic effect of the chemotherapeutic.
Treatment with RAD001 inhibits MTOR and RPS6KB1 phos-
phorylation, increasing the formation of autophagosomes and
the expression of LC3-II in Ishikawa and HEC-1A cells.
Moreover, both treatment with CQ or ATG5 shRNA knock-
down inhibits RAD001-induced cell death. Altogether, these
data indicate that RAD001 may potentially be used for treat-
ing EC patients that present hyperactivated AKT-MTOR
signaling.
Cancer stem cells. Another major contributor to chemoresis-
tance and recurrence is the presence of cancer stem cells
within the tumor. Although the relationship between cancer
stem cells and autophagy has been explored, a complete
understanding of the context of EC is lacking. The first key
step toward this line of research was recently undertaken by
Ran X et al. [91]. Endometrial PROM1/CD133 (prominin 1)-
positive and CD44 (CD44 molecule [Indian blood group])-
positive (PROM1+ CD44+) JEC cells present higher levels of
autophagy, increased BECN1, ATG5, ATG7 mRNA, and LC3-
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II protein levels. Furthermore, the authors demonstrated that
autophagy increases during serial passages of spheroid cul-
tures in vitro and that autophagy inhibition by using CQ
decreases stemness. Knockdown KIAA1324 reduces autop-
hagy levels, as well as the stemness and the tumorigenic
potential of PROM1+ CD44+ EC cells.
Metabolism. Metabolic reprogramming is a hallmark of can-
cer. Several changes in cellular bioenergetics of cancer cells
allow them to adapt to adverse conditions. Cells reprogram
metabolic pathways in order to survive and proliferate under
nutrient-restrictive conditions. Metabolic reprogramming also
alters cellular resistance to hypoxia, oxidative stress, and pro-
motes immunological scape [92].
Metformin is a biguanide hypoglycemic drug commonly
used for the treatment of patients with type-2 diabetes. It
works by decreasing the blood glucose levels and by increasing
sensitivity to insulin of body tissues. Interestingly, metformin
also reduces the proliferation of cancer cells and improves
patient survival [93]. It is also associated with a decreased
incidence of cancer in diabetic patients [94]. Metformin acts
through direct activation of the AMP-activated protein kinase
(AMPK), and inhibition of the MTOR pathway [95,96].
Metformin treatment in Ishikawa cells reduces proliferation
through caspase-dependent apoptosis and cell-cycle arrest at
G0/G1 and G2/M by activating CDKN1A (cyclin dependent
kinase inhibitor 1A) via a TP53-independent pathway [97].
Moreover, metformin induces autophagy activity, by increasing
the ratio LC3-II:LC3-I, SQSTM1 degradation, and the forma-
tion of acidic vesicular organelles. Not surprisingly, inhibition
of metformin-induced autophagy, by 3-methyladenine (3-MA)
treatment or BECN1 siRNAs, reduces apoptosis in Ishikawa EC
cells. These results point to metformin as a promising agent in
the treatment of early EC.
The pharmacological modulation of key enzymatic activ-
ities, such as GCG/GLP1 (glucagon), has also been shown to
impact autophagy in endometrial cells. Together with GIP
(gastric inhibitory polypeptide), GCG represents an incretin
that decreases blood glucose levels by enhancing the secretion
of INS (insulin) [98] and suppression of glucagon secretion
and appetite. As opposed to GIP, GCG activity is preserved in
patients with type-2 diabetes, and GCG analogs are a primary
glycemic control agent for this pathology. The impact of
liraglutide, a derivative of GCG that is used as a long-acting
GLP1R (glucagon-like peptide-1 receptor) agonist, was
recently assessed in Ishikawa EC cells [99]. Liraglutide upre-
gulates the rate of early apoptosis; it arrests Ishikawa cells in
the S phase and significantly induces autophagy by increasing
LC3 expression and p-PRKAA/AMPKα (Thr172), and by
decreasing SQSTM1 protein levels. The combination of lira-
glutide and 5-aminoimidazole-4-carboximide riboside
(AICAR), an AMPK activator, increases the rate of early
apoptosis, and enhances autophagosome accumulation, com-
pared with liraglutide alone. This data indicates that liraglu-
tide-induced autophagy might be involved in the induction of
cell death. The use of liraglutide to target autophagy could be
a potential strategy for EC treatment.
Regarding cellular metabolism, a recent study by Zhou
et al. demonstrated that estrogen increases GLS (glutaminase)
levels through MYCBP (MYC-binding protein) upregulation,
thereby enhancing glutamine metabolism in Ishikawa cells
[100]. First, the authors observed that estrogen exposure pro-
motes cell viability and inhibits autophagy in EC cells by
decreasing LC3B and BECN1 and increasing SQSTM1 levels
and autophagosome and autolysosome structures. Exposing
the cells to fulvestrant, an ESR1 inhibitor antagonist, reverses
the effects, whereas exposure to glutamine enhances cell via-
bility and inhibits the expression of BECN1, LC3B, and
increased SQSTM1. However, treatment with CB-839,
a selective oral bioavailable inhibitor of GLS splice variants,
negatively regulates glutamine metabolism and inhibits the
associated effects of glutamine and estrogen on growth and
autophagy both in vitro and in vivo.
Ginsenosides, derivate compounds from ginseng, have
demonstrated anti-tumoral activities in several cancers.
Protopanaxadiol (PPD), which belongs to the dammarane-
type ginsenosides, exerts anti-tumoral activity in EC and
acts synergistically with metformin [101]. Since ginsenosides
contain a steroidal backbone, they can exert their functions
through interactions with steroidal receptors. In fact, PPD
plays an antiestrogenic effect and synergizes with tamoxifen
in breast cancer cells [102]. In Ishikawa and RL95-2 EC cell
lines, PPD and metformin decrease cell viability and induce
apoptosis and autophagy by increasing BECN1 protein
expression and LC3B-II:LC3B-I ratio. The inhibitory effect
of metformin is further increased in combination with PPD.
The authors observed that PPD and metformin synergistically
regulate the effect of estrogen on Ishikawa and RL95-2 by
decreasing the expression of ESR1 (estrogen receptor 1).
Combination of PPD and metformin result in decreased
tumor growth in Ishikawa cells when subcutaneously injected
in mice, compared with both treatments alone.
Progestins. Progesterone therapy is a conservative non-surgical
treatment used in patients with early-stage, low-grade, hormone
receptor-positive tumors in women who want to maintain their
fertility [103]. It is also used as palliative therapy in patients at
advanced stages. However, about 30% of these patients are
resistant to progesterone treatment [104]. Deciphering themole-
cular mechanisms of resistance and finding solutions to over-
come progesterone resistance represents an urgent clinical need
in medical oncology. In this regard, previous studies by Zhuo
Z et al. demonstrated that metformin suppresses proliferation,
induces cell cycle arrest at G0/G1 and G2/M, and increases
apoptosis and autophagy in progesterone-resistant EC cells
[105]. This result demonstrates the potential use of metformin
in the treatment of progesterone-resistant EC through the mod-
ulation of autophagy.
Progestins play key roles in EC treatment as they bind to
the progesterone receptor and consequently inhibit cell pro-
liferation and induce autophagy. Liu H et al. reported that
long-term exposure to progestin promotes resistance to treat-
ment by activating the PIK3CA-AKT-MTOR signaling path-
way, which, in turn, inhibits autophagy [106]. The authors
observed that inhibition of the PIK3CA-AKT-MTOR path-
way, by means of MTOR knockdown or pharmacological
inhibition using RAD001 (everolimus), re-sensitizes proges-
tin-resistant cells to progestins. Similar to other groups [107],
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the authors generated progestin-resistant cells by exposing EC
cells to long-term medroxyprogesterone acetate (MPA) treat-
ment. Importantly, MPA treatment significantly suppresses
cell proliferation and cell viability, and induces autophagy in
the parental Ishikawa cells but not in progestin-resistant cells,
indicating that long-term progestin treatment might decrease
progesterone receptor expression levels and activate compen-
satory pathways to stimulate cell proliferation and inhibit
autophagy.
Kinases. Kinases represent a growing area of study in the
oncology field. Due to a role in sustaining proliferation and
survival of cancer cells, kinases have been reformed into
coveted targets for the development of novel anticancer
compounds [108,109]. Although kinase inhibitors are consid-
ered the major class of novel cancer drugs, it has been
described that most tumors can escape single kinase inhibi-
tion [109]. Interestingly, in chronic myeloid leukemia and
gastrointestinal stromal tumors, which are driven by a single
oncogenic kinase, the use of kinase inhibitors presented
multi-year increases in survival [110–112]. Survival improve-
ments have also been observed in renal cell carcinoma and
other types of cancers that are highly dependent on the
angiogenesis process [113–115]. However, in several tumor
types like breast, colorectal, lung, pancreatic, prostate, and EC,
kinase inhibitors only exhibited modest results [116–122]. In
EC, treatments with kinase inhibitors were unsuccessful and








































Figure 3. Illustration of the principal autophagy-related function into the human endometrium. Autophagy has a crucial role in both normal and pathological
endometrium and has been linked to endometrial cancer development.
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refractory cell clones, which are related to increased risk of
relapse.
Sorafenib is an FDA-approvedmultitarget tyrosine and serine/
threonine kinase inhibitor, which presents antiangiogenic proper-
ties in patients with advanced renal cell carcinoma, hepatocellular
carcinoma, and metastatic iodine-resistant thyroid carcinoma
[114,123]. Sorafenib has been postulated as a promising targeted
treatment for EC given the increased expression levels of VEGFA
(vascular endothelial growth factor A) and the prominent role of
the RAS-RAF-MAP3K/MEK-MAPKpathway in EC development
and progression [124–126]. However, sorafenib presents modest
effects in a multi-center phase II clinical trial of advanced uterine
carcinoma patients [122].
The mechanisms of sorafenib resistance have been partially
elucidated and have the potential to improve the outcome of
EC patients [127]. By using bioinformatics analysis and
in vitro/in vivo experimental data, Eritja N et al. demonstrated
that resistance could be related to the autophagy pathway.
Sorafenib treatment results in a dramatic decrease in EIF4E
(eukaryotic translation initiation factor 4E) phosphorylated
levels and reduced cell viability as measure by cellular DNA
loss, increased apoptotic cell numbers, caspase activation and
PARP (poly[ADP-ribose] polymerase) cleavage. These results
indicate that sorafenib is an effective anticancer drug in vitro,
supporting previous results [128]. Nonetheless, before cell
commitment to apoptosis takes place, sorafenib exposure
triggers an increased LC3B lipidation in Ishikawa, HEC-1A
and KLE EC cells, suggesting an increase in autophagosome
formation. This data is supported by the increased immuno-
fluorescence of LC3B-II puncta per cell that enhances after
autophagy inhibition with CQ. Sorafenib treatment increases
SQSTM1 proteolysis, which is reversed by CQ or Baf A1
autophagy inhibitors. Most importantly, a chimeric mRFP-
GFP tandem fluorescent-tagged LC3B construct was also used
to monitor autophagic flux. Under these conditions, autopha-
gosomes are detected as a yellow signal (merged mRFP and
GFP signal). However, under enhanced autophagy, the GFP
signal progressively loses fluorescence due to the lysosomal
acidic and degradative conditions. The mRFP remains par-
tially stable, thus labeling autolysosomes in red. Accordingly,
quantification of red (mRFP+ GFP−) and yellow (mRFP+
GFP+) puncta per cell corroborated that sorafenib induces
autophagic flux. Similar results were observed by immuno-
fluorescence, transmitted electron microscopy (TEM), and
immunohistochemistry in 3D cultures and in HEC-1A sub-
cutaneous xenografts. Mechanistically, the authors demon-
strated that the acute autophagy response stems from early
ER stress (XBP1 [X-box binding protein 1] mRNA splicing
and increased DDIT3 [DNA damage inducible transcript 3]
protein levels) and activation of MAPK8/JNK and JUN. Most
importantly, inhibition of MAPK8 (mitogen-activated protein
kinase 8) and MAPK9 (mitogen-activated protein kinase 9) by
using CEP-1347 or by gene editing impairs the formation of
LC3B-II in response to sorafenib. The authors also observed
that autophagy inhibition with CQ or BECN1 shRNA sensi-
tizes EC cells to sorafenib, suggesting that sorafenib activates
an early protective autophagic response that provides cancer
cells with an adaptive response to therapeutic stress. Results
were also validated in vivo in subcutaneous HEC-1A tumors
and metastatic lung models using MFE-296 EC cells. Authors
also generated primary EC orthoxenografts to test the combi-
nation of sorafenib-CQ and demonstrated that autophagy
inhibition enhances sorafenib cytotoxicity and suppresses
tumor growth. In conclusion, sorafenib activates a protective
autophagic response in EC cells and the above results high-
light a new strategy for therapeutic intervention in recur-
rent EC.
Another study focused on the function of SGK1 (serum/
glucocorticoid regulated kinase 1), a serine/threonine protein
kinase that presents homologous function and structure with
the AKT family. It is regulated by PDK1 (pyruvate dehydrogen-
ase kinase 1)-mediated phosphorylation [129], byMTORC1 and
MTORC2 (mechanistic target of rapamycin kinase complex 2),
although more pieces of evidence support the involvement of
MTORC2 [130], and the IGF1-INS pathway [131].
SGK1 and SGK3 (serum/glucocorticoid regulated kinase
family member 3) are involved in the modulation of cell
proliferation and survival in cancer, supporting apoptosis
resistance of cancer cells in hostile tumor microenvironments
[132]. They are both located downstream of the PI3KCA
pathway and interact with the RAS-RAF-ERK pathway and
EGFR (epidermal growth factor receptor) [132]. SGK1 is also
responsible for stimulating the activity of several ion channels,
and its expression is significantly upregulated in EC [133].
A study used an SGK1 inhibitor (SI113) and found that its
administration reduces cell viability in Ishikawa, HEC1-B, and
AN3CA EC cells [129]. In addition, SI113 treatment induces
apoptosis, PARP and CASP9 cleavage, and autophagy through
increased LC3B-II and BECN1 expression. SI113 also upregu-
lates endoplasmic reticulum chaperone HSPA5/BiP (heat
shock protein family A [HSP70] member 5) and DDIT3
protein levels, suggesting that cell viability after SGK1 inhibi-
tion may be compromised by ER stress activation.
Ion channels. Calcium-permeable ion channels and autop-
hagy were reportedly involved in tumor development, pro-
gression, and resistance to chemotherapy [134]. As such,
intracellular Ca2+ can be regarded as a main regulator of
autophagy, and several proteins have been involved in this
regulation (e.g., MTORC1 and CAMKK2 [Ca2+/calmodulin-
dependent protein kinase kinase 2]) [135]. The role of calcium
in autophagy regulation is dependent on a correct spatiotem-
poral Ca2+ availability with a controlled ionic flow between
the extracellular environment, cytosol and storage compart-
ments, growth factors, and nutrient availability, and the type
of pathology [134]. The use of nifedipine, an L-type calcium
channel antagonist, suppresses proliferation in cancer, and its
relation to autophagy, has been studied in EC [136].
Nifedipine inhibits proliferation and migration and increases
apoptosis in HEC-1A cells. In addition, treatment with nife-
dipine significantly induces autophagy by increasing LC3 and
BECN1 expression and decreasing RPS6KB1 levels. Treatment
with 3-MA in HEC-1A decreases the levels of CACNA1D
(calcium voltage-gated channel subunit alpha1 D), evidencing
that its protein expression could be positively regulated by
autophagy. In addition, inhibition of autophagy with 3-MA
increases nifedipine-induced apoptosis and downregulates
BECN1 expression, suggesting that autophagy may function
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as a protective cell survival mechanism. In conclusion,
CACNA1D inhibitors (such as nifedipine) could represent
potential drug candidates in EC targeted therapy.
Others. Recently, a study by Fukuda et al. described the effect
of resveratrol (RSV), a polyphenolic compound derived from
red wine, in EC [137]. RSV inhibits proliferation in Ishikawa
cells, increases the quantity of the sub G1 population, and
activates apoptosis. In addition, RSV exposure induces autop-
hagy, as shown by LC3-II and autophagosome accumulation.
Treatment with both RSV and CQ or knockdown of ATG5 or
ATG7 increases RSV-induced apoptosis significantly, suggest-
ing that RSV-induced autophagy might counteract the anti-
tumor effect of RSV in Ishikawa cells.
Similarly, Wu et al. reported the effects of isoliquiritigenin
(ISL), a natural flavonoid obtained from the root of licorice
(Glycyrrhiza uralensis) with a chalcone structure (4, 20, 40-
trihydroxychalcone). In addition to its anti-oxidant, anti-
inflammatory, and anti-platelet aggregation properties [138–
140], ISL has also been described as an anti-tumoral, inhibitor
of cell growth and apoptosis inducer [141]. As such, ISL induces
cell cycle arrest at the sub G1 and G2/M phases in Ishikawa and
HEC-1A cells, respectively, and apoptosis by increasing the
levels of cleaved CASP3, CASP7 (caspase 7), and PARP [142].
The treatment with ISL also activates the DNA damage marker
H2AX (H2A.X variant histone) and increases TP53 phosphor-
ylation and CDKN1A levels in both cell lines. In addition, ISL
induces autophagy, as shown by increased autophagosomes,
LC3-II levels, and SQSTM1 expression. The authors also
reported that ERK signaling is necessary for ISL-induced apop-
tosis and autophagy. Combination of ISL and Baf A1 slightly
increases ISL-mediated cell cycle arrest and apoptosis in HEC-
1A, suggesting that ISL-induced autophagy plays a cell survival
protective role in tumor cells. Finally, ISL treatment of HEC-1A
subcutaneous xenografts dramatically inhibits tumor growth
when compared to vehicle control.
Considerations and remarks
Despite an increase in studies exploring the role of autophagy
in the endometrium, a significant number of reports are
exclusively based on histological expression analysis or overly
dependent on the use of pharmacological agents such as
chloroquine (CQ), 3-methyladenine (3-MA), or bafilomycin
A1. While this information helps decipher the role of autop-
hagy in the endometrium, the functional conclusions and
insights that can be extracted are far more limited. This is
due, for instance, to the limited assurances that these
approaches can offer to accurately analyze and reliably moni-
tor autophagic flux increased on-rates or decreased off-rates
in contrast to other state-of-the-art methodologies (e.g., tan-
dem GFP-LC3-RFP based techniques) [3,6]. Unfortunately,
a considerable number of studies in EC commonly use static
autophagy techniques (e.g., electron microscopy or LC3-II
immune detection). Although regarded as valuable comple-
mentary information, these techniques are generally consid-
ered unsuitable for this purpose. Similarly, the same can be
contextualized when performing in vivo analyses. For
instance, pending on the evaluation of probe expression and
time resolution, to the best of our knowledge the monitoring
and quantitation of autophagic flux in the endometrium has
not yet been addressed using genetically modified mouse
models suitable for this purpose, such as the mRFP-GFP-
LC3 [143] or GFP-LC3-RFP-LC3ΔG [144] reporter mice.
Finally, another important question relates to the use of chemi-
cal agents and strategies designed to target autophagy, mainly
3-MA and CQ. Repurposing of CQ derivatives, such as hydroxy-
chloroquine, have reached encouraging results in phase-II clinical
trials [145]. However, limitations in terms of specificity, potency,
and cell penetration in acidic microenvironments have prevented
final approval as a treatment option. Consequently, the therapeutic
potential of autophagy modulation has not been fully exploited.
Additional efforts are being conducted to develop novel com-
pounds with improved specificity and potency. Currently, there is
a focus on compound inhibitors targeting PIK3C3/Vps34 (phos-
phatidylinositol 3-kinase catalytic subunit type 3) [146–149], ULK1
[150,151] or the PIKFYVE (phosphoinositide kinase, FYVE-type
zinc finger containing) [152,153]. These compounds showed pro-
mising preclinical efficacy against multiple cancer cell types, yet
none of them have been previously tested on EC cells. Importantly,
the use of these compounds, or the design of new ones, to study
autophagy in the endometriummay provide the scientific commu-
nity with unanticipated results in the field of EC.Other compounds
used for inhibiting or increasing autophagy are reviewed in detail
elsewhere [6]. In conclusion, more rigorous assessment of the
autophagic flux, as well as additional mechanistic studies, are
necessary to understand the role that autophagy plays in the
endometrium and to ultimately transfer this knowledge into the
clinical setting by designing new drugs.
Conclusions
Currently available data indicates that autophagy represents
a pivotal cellular process that is modulated cyclically during
the menstrual cycle. Autophagy has important implications in
normal uterine function, reproductive biology, and endometrial
atrophy. An increasingly large body of evidence indicates that
autophagy also plays an important role in the development of
endometrial cancer (Figure 3). In this regard, autophagy
impacts endometrial cancer response to standard chemother-
apy/radiotherapy and targeted agents with potential implica-
tions in the immune system, given its immune-modulatory
properties. Additional studies and detailed mechanistic insights
are required to fully elucidate and decipher the function of
autophagy in the endometrium. Improved standardized proto-
cols are also necessary to solve some of the paradoxical con-
clusions that can be drawn from the above studies, especially
regarding the context-dependent roles of autophagy.
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